Search

everythinglearnresearchcommunity

for

Search:↓

GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.

Testosterone may influence COVID-19 severity and outcomes.

Hirsutism in women is often due to hormone sensitivity and has significant psychological effects.

Low-dose oral minoxidil improved hair growth when topical treatments failed.

Sulforaphane from broccoli may help treat certain cancers, hormone issues, and hair loss.

Doctors recommend postoperative radiation for male breast cancer, advise against testosterone for vasomotor symptoms post-adrenalectomy, suggest non-hormonal treatments for atrophic vaginitis after mastectomy, note no specific treatment for anticoagulant-induced hair loss, and call for more research on silicosis from silicon carbide exposure.

Prostate cancer can progress even with low testosterone due to internal hormone production in the tumor.

CB-03-01 is a promising skin cream for treating hormone-related skin problems without causing harmful body-wide effects.

Men, particularly those with hair loss, are more likely to get the virus, and those with prostate cancer may have milder symptoms. Testosterone's role in the disease is unclear, and the virus doesn't seem to harm male fertility. Women with PCOS might be at higher risk. More research is needed.

CK 5/6 expression in breast cancer is linked to negative hormone receptor status and higher tumor grade.

Hair growth is influenced by hormones and goes through different phases; androgens can both promote and inhibit hair growth depending on the body area.

The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.

Vitex negundo has potential health benefits, including anti-inflammatory and anti-cancer effects.

Skin problems in the elderly are unique and may indicate other diseases, involving changes in skin, hair, nails, and increased cancer risk.

Circadian rhythm disruption, chronic inflammation, hormones, metabolism, and genetics may increase prostate cancer risk.

The document concludes that non-operative treatment for gender dysphoria is safe and effective, and hormone therapy does not increase cancer risk.

The skin's layers protect, sense, and regulate the body's internal balance, but can be prone to cancer.

Tumor proteins can both promote and suppress cancer, depending on the situation.

The May issue discussed publishing agreements and four studies on cholesterol in hair, cancer cell changes, hormones in the uterus, and skin protein effects.

The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.

Dihydrotestosterone (DHT) mainly affects nearby cells, doesn't significantly change prostate hormonal environment or cancer risk, and doesn't play a main role in causing hair loss or acne. More research is needed on its effects on heart health, sexual function, and bone health.

Hormone therapy for transgender females increases the risk of blood clots and requires careful dosing, monitoring, and lifelong management.

Hormones are crucial for regulating body functions and imbalances can lead to health issues.

Sex hormones affect reproduction, sexual development, and oral health, and it's important for dental practitioners to understand their effects and interactions.

Exposure to certain sex hormones can increase health risks, while some hormone therapies may offer benefits for specific conditions.

The vitamin D receptor has many roles in the body beyond managing calcium, affecting the immune system, hair growth, muscles, fat, bone marrow, and cancer cells.

Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.

Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.

Steroid-producing capabilities in certain cancers may contribute to treatment resistance.